Related Experiment Video

Updated: Jul 11, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

Structural and functional alterations in the beta2-adrenoceptor are caused by a point mutation in patients with

Karin U Schallreuter1, Yuwang Wei, Mark R Pittelkow

  • 1Clinical and Experimental Dermatology, Department of Biomedical Sciences, University of Bradford, Bradford, UK. k.schallreuter@bradford.ac.uk

Experimental Dermatology
|September 12, 2007
PubMed

Insights

Atopic eczema is linked to a specific gene mutation affecting beta2-adrenoceptors. This genetic change impairs the skin's response to adrenergic signals, impacting cellular function in patients.

Area of Science:

  • Genetics
  • Dermatology
  • Pharmacology

Background:

  • Decreased beta2-adrenoceptor density observed in atopic eczema patients' skin and blood cells.
  • Increased antagonist binding affinity (K(D)) noted in affected cells compared to healthy controls.

Purpose of the Study:

  • Investigate potential genetic polymorphism in the beta2-adrenoceptor gene in atopic eczema.
  • Determine the functional impact of identified mutations on cellular response.

Main Methods:

  • Isolation and sequencing of the beta2-adrenoceptor gene from patients and controls.
  • RT-PCR for gene expression analysis.
  • Computer modeling of protein structure.
  • In vitro culture of epidermal keratinocytes to assess phenylalanine sensitivity.

Main Results:

  • A specific point mutation (Ala119Asp) in the beta2-adrenoceptor gene was identified in atopic eczema patients.
  • This mutation causes structural changes in the receptor, affecting its binding site.
  • Keratinocytes from patients exhibited heightened sensitivity to L-phenylalanine, indicating altered adrenergic response.

Conclusions:

  • Atopic eczema is associated with a single point mutation in the beta2-adrenoceptor gene.
  • The identified mutation leads to impaired adrenergic signaling in the epidermis.
  • This genetic defect contributes to the pathophysiology of atopic eczema.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...